Article
A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.
PloS one - 1 Jan 2012
Wang Ena, Zhao Yingdong, Monaco Alessandro, Uccellini Lorenzo, Kirkwood John M, Spyropoulou-Vlachou Maria, Panelli Monica C, Marincola Francesco M, Gogas Helen
Abstract excerpt
PURPOSE: IFNa was the first cytokine to demonstrate anti-tumor activity in advanced melanoma. Despite the ability of high-dose IFNa reducing relapse and mortality by up to 33%, large majority of patients experience side effects and toxicity which outweigh the benefits. The current study attempts to identify genetic markers likely to be associated with benefit from IFN-a2b treatment and predictive for survival....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.